STAT+: FDA warns GLP-1 drugs carry potential risk of rare eye condition
The agency has found evidence of a potential increased risk of a rare eye condition linked to the use of GLP-1 drugs used for weight management and diabetes.
Key points
- GLP-1 drugs such as Novo Nordisk’s Ozempic and Wegovy and Eli Lilly’s Mounjaro and Zepbound have exploded in popularity for their potent weight loss effects, but as with any drugs that are given to large populations, side effects can show up in real-world use that weren’t observed in clinical trials.
- The condition, called non-arteritic anterior ischemic optic neuropathy, or NAION, is sometimes referred to as an “eye stroke” and is caused by insufficient blood flow to the optic nerve.
- Continue to STAT+ to read the full story….
The Food and Drug Administration on Monday warned that GLP-1 drugs carry a potential risk for a rare but serious eye condition and required pharma companies to inform patients and doctors of the risk.
It typically causes sudden vision loss and, in severe cases, can lead to blindness.
How this summary was made: extractive summary — built from the sources' own reporting. It is drawn only from the reporting of the sources listed below — read the originals for full detail. How we summarize →
Advertisement
Every article behind this summary — 2 articles from 2 outlets
Get stories like this in your inbox.
Subscribe — it's freeOne free email at 6am — your topics, deduplicated, five minutes. No account, no paywall.